Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

• Status: Unknown status
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: All

Summary

In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.

To compare effect (ocular surface damage) and safety of preservative-free Latanoprost/Tafluprost to Benzalkonium chloride-preserved Latanoprost in primary open angle glaucoma or normal tension glaucoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taejoon Pharmaceutical Co., Ltd.
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

• Male or female diagnosed with glaucoma, age 19 or over

• Written informed consent to participate in the trial

Exclusion Criteria:

• Patients who have received or have plans lacrimal puntual occulsion

• Use of contact lenses

• Any other Glaucoma except primary open angle glaucoma/normal tension glaucoma (ex) Closed anterior chamber angle/ angle-closure Glaucoma)

• Any condition limiting patient's ability to participate in the trial